MAGEA3 and non-small cell lung carcinoma: MAGEA3 serves as an example; although a clinical trial of an immunotherapy targeting MAGEA3 was suspended because it failed to improve the survival of patients with non-small cell lung cancer, MAGEA3 was recently reported to be necessary for cancer cell viability and sufficient to drive the tumorigenic properties of non-cancerous cells44.